



JC04 Rec'd PCT/PTO 11 JUL 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

JHOTI et al.

Atty. Ref.: 620-374

Serial No. 10/539,447

Group: To be assigned

Filed: June 20, 2005

Examiner: To be assigned

For: SYNTHESIS AND SCREENING OF LIGANDS USING X-RAY CRYSTALLOGRAPHY

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 11, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:


- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

JHOTI et al.
Serial No. 10/539,447

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-374

10/539,447

APPLICANT

JHOTI et al.

(Use several sheets if necessary)

FILING DATE

GROUP

June 20, 2005

To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,350,747	02/2002	Glennon et al.			
	5,958,702	09/1999	Benner			
	6,297,021	10/2001	Nienaber et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/15500	04/1999	WIPO				
	WO 02/42773	05/2002	WIPO				
	WO 00/39585	07/2000	WIPO				
	WO 00/00823	01/2000	WIPO				
	WO 99/49314	09/1999	WIPO				
	WO 97/43232	11/1997	WIPO				
	WO 02/20435	03/2002	WIPO				
	WO 01/64605	09/2001	WIPO				
	EP 1 184 359	03/2002	Europe				
	EP 1 130 009	09/2001	Europe				
	EP 1 188 769	03/2002	Europe				
	WO 99/45389	09/1999	WIPO				
	WO 02/077270	10/2002	WIPO				
	WO 03/033437	04/2003	WIPO				
	WO 03/034071	04/2003	WIPO				
	WO 03/086612	10/2003	WIPO				
	WO 99/45379	09/1999	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Cousins et al, Chem. Commun., 1999, Vol. 16, pp 1575-1576
	Nguyen et al, Chemical Communications, 2003, Vol. 8, pp 942-943
	Babine et al, Letters in Drug Design & Discovery, 2004, Vol. 1(2), pp 173-177
	Lindstrom, Chemical Reviews, 2002, Vol. 102(8), pp 2751-2771
	Eliseev et al, Chem. Eur. J., 1998, Vol. 4, No. 5, pp 825-834
	Rowan et al, J. Am. Chem. Soc., 1997, Vol. 119, pp 2578-2579
	Ramstrom et al, Nature Reviews Drug Discovery, 2002, Vol. 1, pp 26-36
	Bourne et al, PNAS, 2004, Vol. 101, No. 6, pp 1449-1454
	Choong et al, J. Med. Chem., 2002, Vol. 45, pp 5005-5022

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-374

10/539,447

APPLICANT

JHOTI et al.

(Use several sheets if necessary)

FILING DATE

GROUP

June 20, 2005

To be assigned

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	DeLano et al, Science, 2000, Vol. 287, pp 1279-1283
	Erlanson et al, PNAS, 2000, Vol. 97, No. 17, pp 9367-9372
	Maly et al, PNAS, 2000, Vol. 97, No. 6, pp 2419-2424
	Verlinde et al, In Structure-Based Drug Design (Veerapandian, P., ed.), 1997, pp 365-394
	Verlinde et al, Journal of Computer-Aided Molecular Design, 1992, Vol. 6, pp 131-147
	Nienaber et al, Nature Biotechnology, 2000, Vol. 18(10), pp 1105-1108
	Katz et al, Biochemistry, 1995, Vol. 34, pp 8264-8280
	Katz et al, Nature, 1998, Vol. 391, pp 608-612
	Bunyapaiboonsri et al, CHEMBIOCHEM, 2001, Vol. 2, pp 438-444
	Otto et al, Current Opinion in Chemical Biology, 2002, Vol. 6, pp 321-327
	Lehn et al, Science, 2001, Vol. 291, pp 2331-2332
	Cousins et al, Current Opinion in Chemical Biology, 2000, Vol. 4, pp 270-279
	Karan et al, DDT, 2000, Vol. 5, No. 2, pp 67-75
	Klekota et al, Trends Biotechnol., 1999, Vol. 17, pp 205-209
	Lehn, Chem. Eur. J., 1999, Vol. 5, No. 9, pp 2455-2463
	Ganesan, Angew. Chem. Int. Ed. 1998, Vol. 37, No. 20, pp 2828-2831
	Otto et al, DDT, 2002, Vol. 7, No. 2, pp 117-125
	Berl et al, Chem. Eur. J., 2000, Vol. 6, No. 11, pp 1938-1946
	Berl et al, Eur. J. Org. Chem., 1999, pp 3089-3094
	Brady et al, Chem. Commun., 1996, pp 319-320
	Erlanson et al, Nature Biotechnology, 2003, Vol. 21, pp 308-314
	Congreve et al, Angew. Chem. Int. Ed., 2003, Vol. 42(37), pp 4479-4482
	Eksterowicz et al, Journal of Molecular Graphics and Modelling, 2002, Vol. 20, pp 469-477
	Carr et al, DDT, 2002, Vol. 7, No. 9, pp 522-527
	Nguyen et al, Angew. Chem. Int. Ed., 2001, Vol. 40, No. 9, pp 1774-1776
	Lewis et al, Angew. Chem. Int. Ed., 2002, Vol. 41, No. 6, pp 1053-1057
	Huc et al, Combinatorial Chemistry & High Throughput Screening, 2001, pp 109-130
	Huc et al, Eur. J. Inorg. Chem., 1999, pp 1415-1420
	Huc et al, Proc. Natl. Acad. Sci., 1997, Vol. 94, pp 2106-2110
	Hochgurtel et al, PNAS, 2002, Vol. 99, No. 6, pp 3382-3387
	Greer et al, Journal of Medicinal Chemistry, 1994, Vol. 37, No. 8, pp 1035-1054
	Bramson et al, J. Med. Chem., 2001, Vol. 44, pp 4339-4358
	Blundell et al, Nature Reviews Drug Discovery, 2002, Vol. 1, pp 45-54

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)